Its common to see 'market inefficiencies' in nanocaps. And particularly in biotechs because many institutional investors avoid them totally and SP is very influenced by traders. I wouldn't be surprised if there is some movement related to traders around the upcoming FDA approval.
At first I found it odd and offputting that key employees are renumerated in shares rather than wages, but considering how they have stuck by the company even when its SP foundered I think this indicates how much they believe in its prospects and obviously some of them are very clever so I think this is a good sign.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.759M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500000 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 46000 | 1 |
View Market Depth
| Last trade - 16.21pm 26/06/2025 (20 minute delay) ? |
| UCM (ASX) Chart |
Day chart unavailable